Please ensure Javascript is enabled for purposes of website accessibility

Why Shares in Celgene Corp Are Rocketing Higher Today

By Todd Campbell - Jul 15, 2015 at 10:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Celgene's shares are soaring after announcing its planned acquisition of Receptos and increasing its long-term outlook.

Source: Flickr user Steve Jurvetson.

What's happening: After announcing that it would pony up $7.2 billion for multiple sclerosis drug developer Receptos (NASDAQ: RCPT) and increasing its long-term guidance, shares in Celgene Corporation (CELG) shot higher by 10% earlier today.

Why it's happening: Investors have been waiting to see what Celgene would do with its growing cash stockpile, and Celgene's deal to acquire Receptos for $7.2 billion in cash puts the debate over which company Celgene may target on the back burner -- at least for now.

Through this deal, Celgene lands itself ozanimod, a drug many believe could end up becoming the best-in-class oral therapy for treating relapsing multiple sclerosis.

In mid stage trials, ozanimod delivered impressive efficacy, but even more importantly, it did so with placebo-like safety -- an advantage that could prove critical to winning share in this $17 billion (and growing) market. Results from late stage trials that could support an FDA filing should be available in 2017. 

If results are positive and an approval follows, it remains to be seen just how much of the MS market Celgene could eventually capture -- but it could total in the billions of dollars. Currently, the two top selling oral MS therapies are Biogen's Tecfidera and Novartis' Gilenya, and those drugs delivered annualized sales of $2.4 billion and $3.2 billion in the first quarter, respectively. Because ozanimod could have an arguably better safety profile than both of these drugs, its revenue opportunity may be bigger.

Additionally, ozanimod may be able to eventually carve out sales in other indications too. Studies are under way evaluating its potential as a treatment for ulcerative colitis and Crohn's disease, two indications that Celgene's already targeting with its Otezla and GED-0301.  Overall, ozanimod's potential in MS and irritable bowel diseases has Celgene estimating that ozanimod's peak sales could be between $4 billion and $6 billion annually.

If so, then Celgene believes that ongoing growth in its existing drugs alongside upside from ozanimod will lead to revenue of at least $21 billion and adjusted EPS of at least $13 in 2020. That guidance, which is above the $20 billion in sales and $12.50 in adjusted EPS forecast in January, could mean that Celgene's shares aren't done heading higher. 


Todd Campbell owns shares of Celgene. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.